Suppr超能文献

加味当归贝母苦参丸治疗前列腺癌的临床疗效及其对血清前列腺特异性抗原表达的影响

Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen.

作者信息

Zhao Haiyang, Ren Zhiqiang, Wang Guangwen

机构信息

Department of Urology Surgery, The People's Hospital of Guangrao, Dongying 257300, Shandong, China.

出版信息

Evid Based Complement Alternat Med. 2021 Nov 22;2021:1036068. doi: 10.1155/2021/1036068. eCollection 2021.

Abstract

OBJECTIVE

To observe the clinical effects of Jiawei Danggui Beimu Kushen pills in treating prostate cancer and their influence on the expression of serum prostate specific antigen.

METHODS

A total of 234 prostate cancer patients were selected and randomly divided into observation group and control group, with 117 cases in each group. The control group was given oral bicalutamide tablets, while the observation group was treated with Jiawei Danggui Beimu Kushen pills on the basis of the control group. The treatment efficacy, IPSS score, TCM syndrome score, VAS score, quality-of-life score, and immune function of the two groups were compared before and after treatment. The serum PSA and f-PSA levels of patients before treatment and after 30 days, 90 days, and 180 days of treatment in the two groups were compared. The five-year cumulative survival rate and the incidence of adverse reactions were compared between the two groups.

RESULTS

After treatment, the total effective rate of the observation group was 88.03% (103/117), which was higher than that of the control group 69.23% (81/117); the difference was statistically significant ( < 0.05). After treatment, the IPSS score, TCM syndrome score, and VAS score of the two groups were reduced, and those in the observation group were lower than those in the control group; the difference was statistically significant ( < 0.05). After treatment, the quality-of-life scores of the two groups increased, and the observation group was higher than the control group; the difference was statistically significant ( < 0.05). Before treatment, there was no significant difference in serum PSA levels and f-PSA levels when comparing between the two groups of patients ( > 0.05). With the increase of treatment time, the two index levels of the two groups were gradually decreased. After 180 days of treatment, the two index levels of the two groups of patients were significantly lower than those before treatment, and the two index levels of the observation group were significantly lower than those of the control group; the difference was statistically significant ( < 0.05). After treatment, the levels of IgM and IgA in the two groups were decreased, and the level of IgG was increased. The difference between the two groups in the levels of each index before and after treatment was statistically significant ( < 0.05), and the difference between the two groups in the levels of each index after treatment was also statistically significant ( < 0.05). The five-year cumulative survival rate of the observation group was 69.23%, and the five-year cumulative survival rate of the control group was 46.15% ( < 0.05). There was no statistically significant difference between the two groups in the incidence of dizziness, fatigue, and gastrointestinal reactions ( > 0.05), but the difference in the incidence of dysuria as well as dysuria and hematuria was statistically significant ( < 0.05).

CONCLUSION

Jiawei Danggui Beimu Kushen pills are effective in treating prostate cancer, which can effectively reduce the patients' IPSS score and TCM syndrome scores, relieve the pain, and improve the quality of life of patients. They also have a potential role in regulating serum PSA levels, clearing tumor lesions, reducing postoperative complications, and improving related symptoms.

摘要

目的

观察加味当归贝母苦参丸治疗前列腺癌的临床疗效及其对血清前列腺特异性抗原表达的影响。

方法

选取234例前列腺癌患者,随机分为观察组和对照组,每组117例。对照组口服比卡鲁胺片,观察组在对照组基础上加用加味当归贝母苦参丸治疗。比较两组治疗前后的治疗疗效、国际前列腺症状评分(IPSS)、中医证候评分、视觉模拟评分(VAS)、生活质量评分及免疫功能。比较两组患者治疗前及治疗30天、90天、180天后的血清前列腺特异性抗原(PSA)和游离前列腺特异性抗原(f-PSA)水平。比较两组的五年累积生存率及不良反应发生率。

结果

治疗后,观察组总有效率为88.03%(103/117),高于对照组的69.23%(81/117);差异有统计学意义(P<0.05)。治疗后,两组的IPSS评分、中医证候评分及VAS评分均降低,且观察组低于对照组;差异有统计学意义(P<0.05)。治疗后,两组的生活质量评分均升高,且观察组高于对照组;差异有统计学意义(P<0.05)。治疗前,两组患者血清PSA水平及f-PSA水平比较,差异无统计学意义(P>0.05)。随着治疗时间的延长,两组的两项指标水平均逐渐降低。治疗180天后,两组患者的两项指标水平均显著低于治疗前,且观察组的两项指标水平显著低于对照组;差异有统计学意义(P<0.05)。治疗后,两组IgM和IgA水平降低,IgG水平升高。两组各指标治疗前后水平差异有统计学意义(P<0.05),两组治疗后各指标水平差异也有统计学意义(P<0.05)。观察组五年累积生存率为69.23%,对照组五年累积生存率为46.15%(P<0.05)。两组在头晕、乏力及胃肠道反应发生率方面比较,差异无统计学意义(P>0.05),但在排尿困难及排尿困难合并血尿发生率方面差异有统计学意义(P<0.05)。

结论

加味当归贝母苦参丸治疗前列腺癌有效,可有效降低患者的IPSS评分及中医证候评分,缓解疼痛,提高患者生活质量。在调节血清PSA水平、清除肿瘤病灶、减少术后并发症及改善相关症状方面也有潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3ab/8629627/965ff0e12079/ECAM2021-1036068.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验